nach oben

Archives of Virology

Erschienen in:

01.09.2012 | Original Article

Characterization of malleability and immunological properties of human adenovirus type 3 hexon hypervariable region 1

verfasst von: Tianhua Zhong, Xiao Li, Zhichao Zhou, Ting Li, Xingui Tian, Rong Zhou

Erschienen in: Archives of Virology | Ausgabe 9/2012

Einloggen, um Zugang zu erhalten

Abstract

Adenovirus (Ad) capsids that display exogenous epitopes can be potently immunogenic, eliciting a potent humoral response against components of the capsid. We used the epitopes flag, his₆flag, his₆lgsflag and AdV4HVR5 as model antigens to characterize the hexon hypervariable region (HVR) 1 as a site for epitope insertion. A peptide of up to 17 amino acids could be incorporated into HVR1 of the Ad3 hexon without adversely affecting the biological characteristics of the virus. Multiple vaccinations with capsid-modified Ad3 induced a humoral response against the epitope inserted in HVR1. However, antiserum against the his₆flag or his₆lgsflag epitope did not recognize glutathione S-transferase (GST)-his₆ and GST-flag fusion protein. Our study illustrates that there is an immune response against the new epitope within the amino acids of his₆flag or his₆lgsflag epitopes. This discovery could be a warning for the generation of multivalent vaccine vectors by incorporation of multiple epitopes into single HVRs.

Yang Y, Jooss KU, Su Q, Ertl HC, Wilson JM (1996) Immune responses to viral antigens versus transgene product in the elimination of recombinant adenovirus-infected hepatocytes in vivo. Gene Ther 3:137–144PubMed

Schagen FH, Ossevoort M, Toes RE, Hoeben RC (2004) Immune responses against adenoviral vectors and their transgene products: a review of strategies for evasion. Crit Rev Oncol Hematol 50:51–70PubMedCrossRef

Matthews QL, Yang P, Wu Q, Belousova N, Rivera AA, Stoff-Khalili MA, Waehler R, Hsu HC, Li Z, Li J, Mountz JD, Wu H, Curiel DT (2008) Optimization of capsid-incorporated antigens for a novel adenovirus vaccine approach. Virol J 5:98PubMedCrossRef

Worgall S, Krause A, Qiu J, Joh J, Hackett NR, Crystal RG (2007) Protective immunity to Pseudomonas aeruginosa induced with a capsid-modified adenovirus expressing P. aeruginosa OprF. J Virol 81:13801–13808PubMedCrossRef

Chirmule N, Propert K, Magosin S, Qian Y, Qian R, Wilson J (1999) Immune responses to adenovirus and adeno-associated virus in humans. Gene Ther 6:1574–1583PubMedCrossRef

Chen P, Kovesdi I, Bruder JT (2000) Effective repeat administration with adenovirus vectors to the muscle. Gene Ther 7:587–595PubMedCrossRef

Rux JJ, Burnett RM (2004) Adenovirus structure. Hum Gene Ther 15:1167–1176PubMedCrossRef

Crawford-Miksza L, Schnurr DP (1996) Analysis of 15 adenovirus hexon proteins reveals the location and structure of seven hypervariable regions containing serotype-specific residues. J Virol 70:1836–1844PubMed

Rux JJ, Kuser PR, Burnett RM (2003) Structural and phylogenetic analysis of adenovirus hexons by use of high-resolution x-ray crystallographic, molecular modeling, and sequence-based methods. J Virol 77:9553–9566PubMedCrossRef

10.

Rux JJ, Burnett RM (2000) Type-specific epitope locations revealed by X-ray crystallographic study of adenovirus type 5 hexon. Mol Ther 1:18–30PubMedCrossRef

11.

Crompton J, Toogood CI, Wallis N, Hay RT (1994) Expression of a foreign epitope on the surface of the adenovirus hexon. J Gen Virol 75(Pt 1):133–139PubMedCrossRef

12.

Wu H, Han T, Belousova N, Krasnykh V, Kashentseva E, Dmitriev I, Kataram M, Mahasreshti PJ, Curiel DT (2005) Identification of sites in adenovirus hexon for foreign peptide incorporation. J Virol 79:3382–3390PubMedCrossRef

13.

Shiratsuchi T, Rai U, Krause A, Worgall S, Tsuji M (2010) Replacing adenoviral vector HVR1 with a malaria B cell epitope improves immunogenicity and circumvents preexisting immunity to adenovirus in mice. J Clin Invest 120:3688–3701PubMedCrossRef

14.

McConnell MJ, Danthinne X, Imperiale MJ (2006) Characterization of a permissive epitope insertion site in adenovirus hexon. J Virol 80:5361–5370PubMedCrossRef

15.

Yu L, Shimozato O, Li Q, Kawamura K, Ma G, Namba M, Ogawa T, Kaiho I, Tagawa M (2007) Adenovirus type 5 substituted with type 11 or 35 fiber structure increases its infectivity to human cells enabling dual gene transfer in CD46-dependent and -independent manners. Anticancer Res 27:2311–2316PubMed

16.

Rein DT, Breidenbach M, Curiel DT (2006) Current developments in adenovirus-based cancer gene therapy. Future Oncol 2:137–143PubMedCrossRef

17.

Kawakami Y, Li H, Lam JT, Krasnykh V, Curiel DT, Blackwell JL (2003) Substitution of the adenovirus serotype 5 knob with a serotype 3 knob enhances multiple steps in virus replication. Cancer Res 63:1262–1269PubMed

18.

Takayama K, Reynolds PN, Short JJ, Kawakami Y, Adachi Y, Glasgow JN, Rots MG, Krasnykh V, Douglas JT, Curiel DT (2003) A mosaic adenovirus possessing serotype Ad5 and serotype Ad3 knobs exhibits expanded tropism. Virology 309:282–293PubMedCrossRef

19.

Tomko RP, Xu R, Philipson L (1997) HCAR and MCAR: the human and mouse cellular receptors for subgroup C adenoviruses and group B coxsackieviruses. Proc Natl Acad Sci USA 94:3352–3356PubMedCrossRef

20.

Fechner H, Haack A, Wang H, Wang X, Eizema K, Pauschinger M, Schoemaker R, Veghel R, Houtsmuller A, Schultheiss HP, Lamers J, Poller W (1999) Expression of coxsackie adenovirus receptor and alphav-integrin does not correlate with adenovector targeting in vivo indicating anatomical vector barriers. Gene Ther 6:1520–1535PubMedCrossRef

21.

Sirena D, Lilienfeld B, Eisenhut M, Kalin S, Boucke K, Beerli RR, Vogt L, Ruedl C, Bachmann MF, Greber UF, Hemmi S (2004) The human membrane cofactor CD46 is a receptor for species B adenovirus serotype 3. J Virol 78:4454–4462PubMedCrossRef

22.

Hemminki O, Bauerschmitz G, Hemmi S, Lavilla-Alonso S, Diaconu I, Guse K, Koski A, Desmond RA, Lappalainen M, Kanerva A, Cerullo V, Pesonen S, Hemminki A (2011) Oncolytic adenovirus based on serotype 3. Cancer Gene Ther 18:288–296PubMedCrossRef

23.

Tuve S, Wang H, Ware C, Liu Y, Gaggar A, Bernt K, Shayakhmetov D, Li Z, Strauss R, Stone D, Lieber A (2006) A new group B adenovirus receptor is expressed at high levels on human stem and tumor cells. J Virol 80:12109–12120PubMedCrossRef

24.

Kanerva A, Mikheeva GV, Krasnykh V, Coolidge CJ, Lam JT, Mahasreshti PJ, Barker SD, Straughn M, Barnes MN, Alvarez RD, Hemminki A, Curiel DT (2002) Targeting adenovirus to the serotype 3 receptor increases gene transfer efficiency to ovarian cancer cells. Clin Cancer Res 8:275–280PubMed

25.

Tuve S, Wang H, Jacobs JD, Yumul RC, Smith DF, Lieber A (2008) Role of cellular heparan sulfate proteoglycans in infection of human adenovirus serotype 3 and 35. PLoS Pathog 4:e1000189PubMedCrossRef

26.

Zhu ZB, Mathis JM, Makhija SK, Lu B, Wang M, Ji S, Rivera AA, Rosenthal EL, Siegal GP, Curiel DT (2007) Targeting of a conditionally replicative adenovirus agent to human squamous cell carcinomas of the head and neck. Int J Oncol 31:1213–1222PubMed

27.

Zhang Q, Su X, Seto D, Zheng BJ, Tian X, Sheng H, Li H, Wang Y, Zhou R (2009) Construction and characterization of a replication-competent human adenovirus type 3-based vector as a live-vaccine candidate and a viral delivery vector. Vaccine 27:1145–1153PubMedCrossRef

28.

Eswar N, Webb B, Marti-Renom MA, Madhusudhan MS, Eramian D, Shen MY, Pieper U, Sali A (2006) Comparative protein structure modeling using Modeller. Curr Protoc Bioinformatics Chapter 5:Unit 56

29.

Pichla-Gollon SL, Drinker M, Zhou X, Xue F, Rux JJ, Gao GP, Wilson JM, Ertl HC, Burnett RM, Bergelson JM (2007) Structure-based identification of a major neutralizing site in an adenovirus hexon. J Virol 81:1680–1689PubMedCrossRef

30.

Wu H, Dmitriev I, Kashentseva E, Seki T, Wang M, Curiel DT (2002) Construction and characterization of adenovirus serotype 5 packaged by serotype 3 hexon. J Virol 76:12775–12782PubMedCrossRef

31.

Huang XH, Shi ZB, Wang KZ, Dang XQ, Yang P, Yu PB (2008) Construction and identification of recombinant adeno-associated virus vector co-expressing human vascular endothelial growth factor and green fluorescent protein. Journal of clinical rehabilitative tissue engineering research 12:5755–5758

32.

Youil R, Toner TJ, Su Q, Chen M, Tang A, Bett AJ, Casimiro D (2002) Hexon gene switch strategy for the generation of chimeric recombinant adenovirus. Hum Gene Ther 13:311–320PubMedCrossRef

33.

Sette A, Fikes J (2003) Epitope-based vaccines: an update on epitope identification, vaccine design and delivery. Curr Opin Immunol 15:461–470PubMedCrossRef

34.

Aguilar LK, Guzik BW, Aguilar-Cordova E (2011) Cytotoxic immunotherapy strategies for cancer: mechanisms and clinical development. J Cell Biochem 112:1969–1977PubMedCrossRef

Titel: Characterization of malleability and immunological properties of human adenovirus type 3 hexon hypervariable region 1
verfasst von: Tianhua Zhong
Xiao Li
Zhichao Zhou
Ting Li
Xingui Tian
Rong Zhou
Publikationsdatum: 01.09.2012
Verlag: Springer Vienna
Erschienen in: Archives of Virology / Ausgabe 9/2012
Print ISSN: 0304-8608
Elektronische ISSN: 1432-8798
DOI: https://doi.org/10.1007/s00705-012-1364-1

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Herzinfarkt mit 85 – trotzdem noch intensive Lipidsenkung?

16.05.2024 Hypercholesterinämie Nachrichten

Profitieren nach einem akuten Myokardinfarkt auch Betroffene über 80 Jahre noch von einer intensiven Lipidsenkung zur Sekundärprävention? Um diese Frage zu beantworten, wurden jetzt Registerdaten aus Frankreich ausgewertet.

ADHS-Medikation erhöht das kardiovaskuläre Risiko

16.05.2024 Herzinsuffizienz Nachrichten

Erwachsene, die Medikamente gegen das Aufmerksamkeitsdefizit-Hyperaktivitätssyndrom einnehmen, laufen offenbar erhöhte Gefahr, an Herzschwäche zu erkranken oder einen Schlaganfall zu erleiden. Es scheint eine Dosis-Wirkungs-Beziehung zu bestehen.

Bei Herzinsuffizienz muss „Eisenmangel“ neu definiert werden!

16.05.2024 Herzinsuffizienz Nachrichten

Bei chronischer Herzinsuffizienz macht es einem internationalen Expertenteam zufolge wenig Sinn, die Diagnose „Eisenmangel“ am Serumferritin festzumachen. Das Team schlägt vor, sich lieber an die Transferrinsättigung zu halten.

Erstmanifestation eines Diabetes-Typ-1 bei Kindern: Ein Notfall!

16.05.2024 DDG-Jahrestagung 2024 Kongressbericht

Manifestiert sich ein Typ-1-Diabetes bei Kindern, ist das ein Notfall – ebenso wie eine diabetische Ketoazidose. Die Grundsäulen der Therapie bestehen aus Rehydratation, Insulin und Kaliumgabe. Insulin ist das Medikament der Wahl zur Behandlung der Ketoazidose.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 9/2012

Vaccinia virus infection suppresses the cell microRNA machinery

Complete genome sequence of narcissus late season yellows virus infecting Chinese narcissus in China

A novel mycovirus from Clitocybe odora

First report of bovine herpesvirus 5 in bull semen

A novel miRNA produced during lytic HSV-1 infection is important for efficient replication in tissue culture